The conference was held March 31 - April 3 in London.) Company (Location) Product Description Indication Status Date Cempra Inc. (Chapel Hill, N.C.) CEM-101 Solithromycin Community-acquired bacterial infections Data demonstrated efficacy to be comparable to levofloxacin in a Phase II trial 4/3/12 Optimer Pharmaceuticals Inc. (San Diego) Dificid Fidaxomicin tablets Clostridium-difficile-associated diarrhea Phase III data demonstrated that cancer patients had higher clinical cure rates, better
Clavis Pharma ASA, of Oslo, Norway, reported that partner Clovis Oncology Inc., of Boulder, Colo., received notification from the independent data monitoring committee that 64 percent of the 360 metastatic pancreatic cancer patients enrolled in the pivotal LEAP study testing CP-4126 (also known as CO-101) were classified as hENT1-low...The final hENT1 classification is in line with results reported in January showing that about two-thirds of metastatic pancreatic cancer patients are likely to be
TapImmune Inc., of Seattle, said the Mayo Clinic received investigational new drug application allowance for a Phase I trial of the company's HER-2/neu vaccine in breast cancer patients who finished standard Herceptin (trastuzumab, Roche AG)-based therapy and are at high risk of disease recurrence
cancer patients 4/12/12 Vical Inc. (San Diego) Astellas Pharma Inc. (Tokyo) $10 For finalizing the design for a pivotal Phase III trial of TransVax cytomegalovirus vaccine for transplant recipients 4/3/12 Xencor Inc. (Monrovia, Calif.) Boehringer Ingelheim GmbH (Ingelheim, Germany) ND For a regulatory submission to begin Phase I trials of a monoclonal antibody optimized using Xencor's XmAb antibody engineering technology 4/5/12 Xencor Inc. (Monrovia, Calif.) CSL Ltd. (Melbourne, Australia) ND
For instance, Abbott's DNA-based Vysis ALK Break Apart FISH Probe Kit is FDA approved to determine which lung cancer patients should receive ALK inhibitor Xalkori (crizotinib, Pfizer Inc
By Brian Orelli | BioWorld Insight | Monday, April 30, 2012
Adocia SAS, of Lyon, France, reported positive Phase II data for the firm's BioChaperone PDGF-BB, a spray, vs. Regranex, a gel and the only available treatment for diabetic foot ulcer treatment. The trial met the main objectives with a dose reduction by three of the growth factors contained in Regranex and a reduction of the frequency of application, once every two days vs. every day for Regranex. The objective of the study was to establish the noninferiority of BioChaperone PDGF-BB compared to
BioWorld International | Wednesday, April 25, 2012
GvHD, in which immune cells attack donated tissue, occurs in almost half of blood cancer patients undergoing bone marrow transplants, while oral mucositis increases mortality in patients with head and neck cancers because doctors must often stop chemotherapy treatment until the painful wounds heal
By Trista Morrison | BioWorld Today | Friday, April 20, 2012
RedHill Biopharma Ltd., of Tel Aviv, Israel, said a trial of RHB-102 for nausea in cancer patients met its objectives and the FDA criteria for bioequivalence with Zofran (GlaxoSmithKline plc
The company is collaborating with the Mayo Foundation on the clinical evaluation of the antigens in breast cancer patients and holds an option to license the technology
How much their risk was reduced varied by the specific poly-Q disease, but the effect held up across three separate diseases – Huntington's disease, spinobulbar muscular atrophy and hereditary ataxia – over a period of 40 years, leading the authors to conclude that "the consistently decreased incidence of cancer in patients with poly-Q diseases suggests that a common mechanism protects against the development of cancer
cancer patients